ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer ...Middle East

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy...

Read More Details
Finally We wish PressBee provided you with enough information of ( ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer )

Also on site :

• Over 20 feared dead in terror attack targeting tourists in India’s Kashmir
• Glenview man, woman returning home from night out robbed at gunpoint: Police
• Where Is 'Tiger King' Joe Exotic Now and Is He Married? Find Out the Latest on the Ex-Zoo Owner